Novel single day premedication regimen for prevention of paclitaxel- induced hypersensitivity reaction
International Journal of Development Research
Novel single day premedication regimen for prevention of paclitaxel- induced hypersensitivity reaction
Received 15th December, 2016; Received in revised form 26th January, 2017; Accepted 22nd February, 2017; Published online 31st March, 2017
Copyright©2017, Roshan Koshy Jacob et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Paclitaxel is one of the most active chemotherapy agents for the treatment of ovarian and other gynecologic cancers. Hypersensitivity reactions (HSR) remain one of the major clinical concerns in the use of paclitaxel. This report is a retrospective study assessing the rates of hypersensitivity in patients who received paclitaxel in Vydehi Institute of Medical Sciences and Research centre, Bangalore from May 2015 to July 2016. All patients received 2 doses of INJ Dexamethasone 8 mg, Inj Ranitidine 50 mg and Inj Pheniramine Maleate 44.5 mg 3 hours apart on the day of chemotherapy. The primary outcome measure was rate of hypersensitivity. In this series, novel single day premedication for Paclitaxel appeared to be associated with lower rate of hypersensitivity than the conventional premedication regimen.
